Qualigen Therapeutics announces the promotion of Benedict Abugan to Vice President, VP, Head of Diagnostics and Corporate Communications. Abugan has over two decades of experience in medical diagnostics and therapeutics. He joined Qualigen as a scientist in 2000, supporting the feasibility, development, and successful commercialization of several Qualigen FastPack products.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on QLGN:
- Qualigen Therapeutics Initiates Good Laboratory Practice (GLP) Toxicology Studies on QN-302
- Qualigen Therapeutics Promotes Benedict M. Abugan to Vice President, Head of Diagnostics and Corporate Communications
- Qualigen Therapeutics receives orphan drug designation for QN-302
- Qualigen Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for QN-302, a G-Quadruplex (G4) Transcription Inhibitor for the Intended Indication of Pancreatic Cancer
- Qualigen Therapeutics pancreatic cancer treatment granted orphan designation